Successful trial of Parkinson’s treatment

Israeli biotech Pharma Two B has announced positive results in its Phase IIb pivotal clinical study of P2B001 for the treatment of early stage Parkinson’s disease. The tests combined two low dose chemicals that separately had limited effect and were dangerous in high dosages.

http://www.pharma2b.com/en/73/Press_Release_5.aspx

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.